14.27
Schlusskurs vom Vortag:
$12.66
Offen:
$12.61
24-Stunden-Volumen:
106.37K
Relative Volume:
1.33
Marktkapitalisierung:
$432.89M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-1.77M
KGV:
-95.93
EPS:
-0.1487
Netto-Cashflow:
$-1.46M
1W Leistung:
+44.78%
1M Leistung:
+34.49%
6M Leistung:
+303.46%
1J Leistung:
+0.00%
Turn Therapeutics Inc Stock (TTRX) Company Profile
Firmenname
Turn Therapeutics Inc
Sektor
Branche
Telefon
(818) 564-4011
Adresse
250 NORTH WESTLAKE BLVD., WESTLAKE VILLAGE
Compare TTRX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
TTRX
Turn Therapeutics Inc
|
14.26 | 384.46M | 0 | -1.77M | -1.46M | -0.1487 |
|
VRTX
Vertex Pharmaceuticals Inc
|
521.74 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
1,004.21 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
|
MRNA
Moderna Inc
|
137.49 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
RVMD
Revolution Medicines Inc
|
209.88 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Turn Therapeutics Inc Stock (TTRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-29 | Eingeleitet | D. Boral Capital | Buy |
Turn Therapeutics Inc Aktie (TTRX) Neueste Nachrichten
Turn Therapeutics Names Former CDC Director Robert Redfield Chief Scientific Officer - citybiz
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer - BioSpace
Turn Therapeutics Names Robert Redfield Chief Scientific Officer - TipRanks
Former CDC Director Robert Redfield Joins Turn Therapeutics as Chief Scientific Officer - Dermatology Times
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
TTRX - Finviz
Turn Therapeutics (NASDAQ:TTRX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Ieq Capital LLC Makes New Investment in Turn Therapeutics Inc. $TTRX - MarketBeat
Turn (TTRX) Levels: Records a 2.33% Increase to $9.68 in the Current Update; Levels: $9.20 and $10.16 Define the Nearby Reference Levels in the Latest SessionContinuation Pattern Picks - vinanet.vn
Turn (TTRX) Session: Records a 0.84% Decrease to $9.46 on the Day; Range Check: Traders Can Monitor the $8.99-$9.93 Range in the Available RecordFibonacci Entry Signals - vinanet.vn
Turn (TTRX) Results Breakdown: Available Metrics Are Broadly in Line for the Current Session; After Earnings: The Stock Ends Down 2.85% at the CloseGuidance Accuracy Score - vinanet.vn
Turn (TTRX) Close: Ends Lower by 0.20% at $9.80 on the Day; Current Setup: Traders Can Monitor the $9.31-$10.29 Range in Latest TradingWedge Breakout - vinanet.vn
GX-03 Selectively Reduces Key Drivers of Skin Inflammation, Itch - The Dermatology Digest
GX-03 Cuts Itch-Related Cytokine IL-31 by Nearly 68% in AD Model - Dermatology Times
Turn Therapeutics publishes study on GX-03 skin therapy - Investing.com
Turn Therapeutics publishes study on GX-03 skin therapy By Investing.com - Investing.com Canada
Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch - Business Wire
Turn Therapeutics Issues 579,664 Shares in Cashless Warrant Exercise - Minichart
Form 8K Turn Therapeutics Inc For: 18 August By Investing.com - Investing.com South Africa
Turn Therapeutics Reports Unregistered Cashless Warrant Share Issuance - TipRanks
Turn Therapeutics Completes Cashless Exercise of GEM Warrant, Issues 579,664 Shares - Kalkine Media
Turn Therapeutics Raises $1.35 Million in Private Placement - Minichart
Turn Therapeutics Secures $1.35 Million Through Private Stock Placement - Kalkine Media
Turn Therapeutics Raises $1.35M Through Private Placement - TipRanks
Turn Therapeutics (TTRX) Rallies 3.55% to $9.91, Approaching Key $10.41 ResistanceBeta Neutral Pair - vinanet.vn
Ladenburg Thalmann Initiates Turn Therapeutics(TTRX.US) With Buy Rating, Announces Target Price $16 - Moomoo
Turn Therapeutics (NASDAQ:TTRX) Stock Price Down 6.5%Time to Sell? - MarketBeat
Turn Therapeutics Inc. announced that it expects to receive $1.35 million in funding - marketscreener.com
Turn Therapeutics (TTRX) Falls 5.6% to $9.95 as Support at $9.45 Comes into FocusRetracement Entry - vinanet.vn
Turn Therapeutics Announces Q2 2026 Financial Results with Increased Net Loss and Long-Term Debt - Kalkine Media
Form 8K Turn Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
Turn Therapeutics (NASDAQ: TTRX) posts larger loss, adds debt and warns on going concern - Stock Titan
Turn Therapeutics Q2 net loss per share widens on higher R&D costs - TradingView
Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results - Yahoo Finance
Turn Therapeutics Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Turn Therapeutics Rings the Closing Bell - Nasdaq
Turn Therapeutics Ord Shs (TTRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Price to sales forward of Turn Therapeutics Inc. – NASDAQ:TTRX - TradingView
Turn Therapeutics (TTRX) Advances 3.82% to $8.56 as Biotech Buying Interest IntensifiesValue ETF - vinanet.vn
Turn Therapeutics Inc. Revenue Breakdown – NASDAQ:TTRX - TradingView
Turn Therapeutics Updates GX-03 Investor Presentation and Pipeline - TipRanks
Turn updates investor presentation, cites Q4 2026 AD Phase 2 topline and $11.2M cash - TradingView
GX-03 trial data and cash runway at Turn Therapeutics (NASDAQ: TTRX) - Stock Titan
Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026 - Business Wire
Turn Therapeutics Ord Shs (TTRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TTRX|Turn Therapeutics Ord Shs|Price:9.575|Chg%:+0.735 - TradingKey
Turn Therapeutics (TTRX) Plunges Nearly 10% as Stock Approaches Key Support ZoneFactor Momentum - vinanet.vn
TTRX Forecast — Price Target — Prediction for 2027 - TradingView
Turn Therapeutics Inc. Common Stock (NASDAQ: TTRX) Stock Price, News & Analysis - Kalkine
Zacks Research Upgrades Turn Therapeutics (NASDAQ:TTRX) to Hold - MarketBeat
Enterprise value to revenue forward of Turn Therapeutics Inc. – NASDAQ:TTRX - TradingView
Finanzdaten der Turn Therapeutics Inc-Aktie (TTRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Turn Therapeutics Inc-Aktie (TTRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| GOLDEN ARTHUR F | Director |
Nov 24 '25 |
Buy |
3.44 |
9,868 |
33,946 |
60,602 |
| GOLDEN ARTHUR F | Director |
Nov 21 '25 |
Buy |
2.87 |
20,532 |
58,927 |
50,734 |
| Chaudhary Zuraiz | See Remarks |
Nov 20 '25 |
Buy |
2.61 |
1,450 |
3,784 |
9,000 |
| Chaudhary Zuraiz | See Remarks |
Nov 21 '25 |
Buy |
3.29 |
1,000 |
3,290 |
10,000 |
| Chaudhary Zuraiz | See Remarks |
Nov 17 '25 |
Buy |
3.62 |
2,500 |
9,050 |
7,550 |
| Chesed Abraham | Board Observer |
Oct 23 '25 |
Buy |
4.60 |
14,286 |
65,716 |
1,447,268 |
| Chaudhary Zuraiz | See Remarks |
Oct 23 '25 |
Buy |
4.95 |
5,050 |
24,998 |
5,050 |
| GOLDEN ARTHUR F | Director |
Oct 23 '25 |
Buy |
4.95 |
20,202 |
100,000 |
30,202 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):